Securities Registration: Employee Benefit Plan (s-8)
May 08 2019 - 12:40PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on May 8, 2019
Registration
No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Core Laboratories N.V.
(Exact name of registrant as specified in its charter)
|
|
|
The Netherlands
|
|
Not Applicable
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
Strawinskylaan 913
Tower A, Level 9
1077 XX Amsterdam
The
Netherlands
(31-20)
420-3191
(Address, including zip code, and telephone number, including
area code, of registrants principal executive offices)
CORE LABORATORIES N.V. 2014 LONG-TERM INCENTIVE PLAN
(Full title of the plan)
Mark F. Elvig
General
Counsel
Core Laboratories LP
6316 Windfern Road
Houston, Texas 77040
(713)
328-2673
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company and emerging growth company in
Rule 12b-2
of the Securities Exchange Act of 1934, as amended (the
Exchange Act).
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated
filer
|
|
☐
(Do not check if smaller reporting company)
|
|
Smaller Reporting Company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging Growth Company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of securities
to be registered
|
|
Amount
to be
registered
(1)
|
|
Proposed
maximum
offering price
per
unit (2)
|
|
Proposed
maximum
aggregate
offering price (2)
|
|
Amount of
registration fee (3)
|
Common Shares (EUR 0.02 par value per share)
|
|
1,800,000
|
|
$59.57
|
|
$107,226,000
|
|
$12,995.79
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), the
additional shares of Common Shares as may become issuable pursuant to the adjustment and anti-dilution provisions of the Core Laboratories N.V. 2014 Long-Term Incentive Plan, as amended from time to time (the Plan) are also being
registered.
|
(2)
|
Estimated solely for purposes of calculating the registration fee in accordance with Rules 457(c) and
(h) under the Securities Act The proposed maximum offering price per share and the proposed maximum aggregate offering price for the 1,800,000 shares being registered hereby is based on a price of $59.57, which is the average of the high and
low prices of our Common Shares as reported by the New York Stock Exchange on May 2, 2019.
|
(3)
|
Pursuant to General Instruction E to Form
S-8,
a registration fee is
only being paid with respect to the registration of an additional 1,800,000 shares of Common Shares under the Plan.
|
EXPLANATORY NOTE
Core Laboratories N.V. (the Registrant), is filing this registration statement on Form
S-8
(this Registration Statement) pursuant to General Instruction E of Form
S-8
to register the offer and sale of an additional 1,800,000 shares of Common Shares that may be issued to employees under
our employee equity incentive plan that will continue to come from treasury shares, but could involve the issuance of new shares, if necessary, under the Plan. Except as otherwise set forth below, the contents of the Registrants registration
statements on Form
S-8
relating to the Plan, which were previously filed with the Securities and Exchange Commission (the Commission) on November 20, 2001 (File
No. 333-73774)
and November 20, 1997 (File
No. 333-40641),
as well as a prior registration statement that is File
No. 33-98590,
are incorporated by reference into this Registration Statement as permitted by General Instruction E of Form
S-8.
PART II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form
S-8
and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Amsterdam,
the Netherlands, on May 7, 2019.
|
|
|
|
|
CORE LABORATORIES N.V., by its sole managing director,
|
CORE LABORATORIES INTERNATIONAL B.V.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jacobus Schouten
|
|
|
Name:
|
|
Jacobus Schouten
|
|
|
Title:
|
|
Managing Director
|
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark F. Elvig as his or her true
and lawful
attorney-in-fact
and agent, with full power of substitution for him and in his name, place and stead, in any and all capacities, to sign any and all
amendments (including post-effective amendments) to this Registration Statement and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact
and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully and to
all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said
attorney-in-fact
and agent or any of them, or their or his
substitute or substitutes may lawfully do or cause to be done by virtue hereof.
[
signatures on next page
]
Pursuant to the requirements of the Securities Act, this Registration Statement and the
above Power of Attorney have been signed below by the following persons in the capacities indicated on May 7, 2019.
|
|
|
Name
|
|
Position
|
/s/ David M. Demshur
David M. Demshur
|
|
Chief Executive Officer and Chairman
(Principal Executive Officer)
|
|
|
/s/ Christopher S. Hill
Christopher S. Hill
|
|
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
|
|
|
/s/ Kevin G. Daniels
Kevin G. Daniels
|
|
Chief Accounting Officer
(
Principal Accounting Officer
)
|
|
|
/s/ Martha Carnes
Martha Carnes
|
|
Director
|
|
|
/s/ Michael Straughen
Michael Straughen
|
|
Director
|
|
|
/s/ Charles L. Dunlap
Charles L. Dunlap
|
|
Director
|
|
|
/s/ Jan Willem Sodderland
Jan Willem Sodderland
|
|
Director
|
|
|
/s/ Lawrence Bruno
Lawrence Bruno
|
|
Director
|
|
|
/s/ Margaret Ann van Kempen
Margaret Ann van Kempen
|
|
Director
|
|
|
/s/ Lucia van Geuns
Lucia van Geuns
|
|
Director
|
SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT
Pursuant to the Securities Act, the undersigned, a duly authorized representative of the Company in the United States, has signed the
Registration Statement in the City of Houston, State of Texas
on the 7th day of May 2019.
|
|
|
By:
|
|
/s/ Mark F. Elvig
|
Name:
|
|
Mark F. Elvig
|
Title:
|
|
General Counsel, Senior Vice President and Secretary
|
Core Laboratories (NYSE:CLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Core Laboratories (NYSE:CLB)
Historical Stock Chart
From Apr 2023 to Apr 2024